Phase III Teriflunomide adjunct therapy with interferon beta
Phase III Teriflunomide adjunct therapy with interferon beta
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2355 Views
-
Last post by frodo
-
- 0 Replies
- 1354 Views
-
Last post by frodo
-
- 0 Replies
- 1798 Views
-
Last post by NHE
-
- 1 Replies
- 3317 Views
-
Last post by Tif
-
- 2 Replies
- 4592 Views
-
Last post by DIM
-
- 0 Replies
- 2625 Views
-
Last post by NHE
-
- 0 Replies
- 1307 Views
-
Last post by NHE
-
- 2 Replies
- 1988 Views
-
Last post by frodo
-
- 0 Replies
- 12704 Views
-
Last post by NHE